deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT06449352

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Effect of the Addition of Netarsudil 0.02% vs. Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005%

Sponsor: Sengi

Conditions Normal Tension Glaucoma
Interventions Brimonidine Netarsudil
Updated 4 times since 2024 Last updated: Oct 21, 2025 Started: Jun 13, 2024 Primary completion: Sep 22, 2025 Completion: Sep 22, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Normal Tension Glaucoma and is currently completed. Sengi leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshotRecruiting~Aug 2025 – ~Nov 2025 · 3 months · monthly snapshotRecruiting~Nov 2025 – present · 8 months · monthly snapshotCompleted

Change History

4 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE4

    Status: Recruiting → Completed

  2. Aug 2025 — Nov 2025 [monthly]

    Recruiting PHASE4

  3. Sep 2024 — Aug 2025 [monthly]

    Recruiting PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE4

    First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sengi
  • Westlake Eye Specialists
Data source: Westlake Eye Specialists

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations